AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3896455
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with vincristin (1.2 mg/m2), Adriamycin (40 mg/m2), cyclophosphamide (500 mg/m2), and medroxyprogesteron acetate (MPA) (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Trial: 3896455
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy with the same combination chemotherapy (VAC) for three cycles alternating with MPA (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Trial: 3896455
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy
Trial: 2905566
Drug: pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 1 mg/kg + atropine 0.01 mg/kg
Trial: 2905566
Drug: pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 1 mg/kg
Trial: 2905566
Drug: d-tubocurarine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tubocurarine 0.5 mg/kg
Trial: 2905566
Drug: alcuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcuronium 0.3 mg/kg
Trial: 2905566
Drug: pancuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pancuronium 0.1 mg/kg
Trial: 2905566
Drug: atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.5 mg/kg
Trial: 27784211
Drug: FDSFs (Fast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDSFs (Fast Dissolving Sublingual Films) containing Pullulan with Maltodextrin in a ratio 3:1
Trial: 27784211
Drug: FDSFs (Fast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDSFs (Fast Dissolving Sublingual Films)
Trial: 27784211
Drug: Ventolin® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventolin® tablets 2 mg
Trial: 21572327
Drug: Initial antibiotics
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotics administered before shock recognition
Trial: 21572327
Drug: Initial antibiotics
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotics administered after shock recognition
Trial: 21572327
Drug: Hourly delays
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly delays in antibiotic administration after shock recognition
Trial: 9279722
Drug: PM inactivated
RxNorm normalized name: rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection [Imovax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM inactivated hepatitis A vaccine
Trial: 9279722
Drug: SB inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB inactivated hepatitis A vaccine
Trial: 29778281
Drug: Water-drinking test
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-drinking test (WDT) in patients on medical treatment for POAG
Trial: 29778281
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (two or more medications)
Trial: 27351217
Drug: 2L treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2L treatment after 1L nab-P+Gem
Trial: 27351217
Drug: 2L treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2L treatment after 1L Gem
Trial: 27351217
Drug: 2L therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2L therapy containing fluoropyrimidine after 1L nab-P+Gem
Trial: 27351217
Drug: 2L therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2L therapy containing fluoropyrimidine after 1L Gem
Trial: 23775961
Drug: Pemetrexed (P)
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed (P) 500 mg/m²
Trial: 23775961
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and Pemetrexed (CP) AUC 5 and 500 mg/m²
Trial: 18256069
Drug: Infliximab at
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab at 3 and 5 mg/kg body weight administered over 24 weeks
Trial: 12942031
Drug: Bilevel therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilevel therapy
Trial: 10481861
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with daunorubicin 45 mg/m2 (group 1, trial 2)
Trial: 10481861
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with daunorubicin 60 mg/m2 (group 3, trial 2)
Trial: 10481861
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with daunorubicin 45 mg/m2 (group 2, trial 2)
Trial: 1952845
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of ketoconazole alone
Trial: 1952845
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of sucralfate with 400 mg of ketoconazole
Trial: 1952845
Drug: Ranitidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine administered 2 h prior to 400 mg of ketoconazole
Trial: 30169267
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine (IIV4) - 15 μg haemagglutinin antigen per strain per 0.5 mL dose; single dose on day 0 for vaccine-primed children, and two doses on days 0 and 28 for vaccine-unprimed children.
Trial: 30169267
Drug: Non-influenza control
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-influenza control vaccine (one or two doses).
Trial: 27221874
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (SQT)
Trial: 27221874
Drug: 14-day standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day standard triple therapy (STT)
Trial: 24262967
Drug: Sibutramine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine therapy
Trial: 17074778
Drug: Spray disinfection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spray disinfection with 2-propanol and benzalkonium chloride (SP)
Trial: 12001325
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (IPC) as an adjuvant therapy
Trial: 9787885
Drug: Low-dose ECT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ECT
Trial: 7897158
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium (120 mg, by mouth, daily)
Trial: 2698894
Drug: Lidocaine periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine periodontal ligament injections
Trial: 2698894
Drug: Epinephrine periodontal
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine periodontal ligament injections
Trial: 4802389
Drug: 1000 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 CCA unit Aichi/68 influenza vaccine
Trial: 4802389
Drug: 1000 CCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 CCA unit Japan/57 influenza vaccine
Trial: 27449500
Drug: Adjunctive peri-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive peri-operative steroid combination (triamcinolone acetonide) 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml into the sub-Tenon's space.
Trial: 27449500
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment and routine pre-operative and post-operative treatment and care.
Trial: 19833214
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/d)
Trial: 20547795
Drug: Fixed-dose artesunate-mefloquine
RxNorm normalized name: artesunate and mefloquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose artesunate-mefloquine (AS-MQ) - 100 mg AS and 200 mg MQ/tablet daily for 3 days (days 0, 1, and 2)
Trial: 20547795
Drug: Nonfixed artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nonfixed artesunate plus mefloquine (AS-plus-MQ) - 4 mg/kg AS/day for 3 days plus 15 mg/kg MQ on day 1 and 10 mg/kg on day 2
Trial: 20547795
Drug: Fixed-dose AS-MQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose AS-MQ
Trial: 18543307
Drug: ICD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD treatment in patients with eGFR > 75.0 mL/min/1.73 m² (Group I)
Trial: 18543307
Drug: ICD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD treatment in patients with eGFR 60.0 to 74.9 mL/min/1.73 m² (Group II)
Trial: 18543307
Drug: ICD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD treatment in patients with eGFR 45.0 to 59.9 mL/min/1.73 m² (Group III)
Trial: 18543307
Drug: ICD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD treatment in patients with eGFR ≤ 45.0 mL/min/1.73 m² (Group IV)
Trial: 15878723
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with haloperidol (3‐10 mg/day for 2‐4 months)
Trial: 15878723
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Normal participants with no experience with antipsychotic drugs)
Trial: 12902363
Drug: Cognitive-Behavioral Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Intervention for Trauma in Schools (10-session standardized cognitive-behavioral therapy)
Trial: 9581986
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (Ome20)
Trial: 9581986
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg (Ome10)
Trial: 9581986
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (Ome20) in oesophagitis patients
Trial: 9581986
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg (Ome10) in oesophagitis patients
Trial: 9581986
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up (6 months off treatment)
Trial: 1832753
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment group
Trial: 1832753
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment group
Trial: 6810013
Drug: Sustak 6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustak 6.4 mg
Trial: 28635153
Drug: Silymarin gel
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin gel 1% applied twice daily for 9 weeks
Trial: 20947374
Drug: Vorapaxar (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorapaxar (1 or 2.5 mg) plus aspirin (75-150 mg/day)
Trial: 20947374
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus aspirin (75-150 mg/day)
Trial: 15316750
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral docetaxel combined with 500 mg OC144‐093
Trial: 19509162
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg i.v. docetaxel
Trial: 11172188
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of therapy for 12 weeks
Trial: 11172188
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of therapy
Trial: 2138182
Drug: Enoximone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (0.5 mg/kg single injection, continuous infusion at 5 and 10 micrograms/kg.min)
Trial: 23769325
Drug: Improved adherence
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved adherence to medication
Trial: 8058420
Drug: Albuterol administered
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol administered by metered dose inhaler through a spacer device (Babyhaler)
Trial: 2221865
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (1,000 mg orally) taken 1 hour before a meal (BE)
Trial: 2221865
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (1,000 mg orally) taken with a meal (WI)
Trial: 2221865
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (1,000 mg orally) taken 1 hour after a meal (AF)
Trial: 2221865
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 250 ml
Trial: 2221865
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 450 ml
Trial: 657082
Drug: Cyclophosphamide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (30 mg/kg total dose) given for one six-day course immediately after mastectomy
Trial: 657082
Drug: Cyclophosphamide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (30 mg/kg total dose)
Trial: 657082
Drug: Cyclophosphamide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (30 mg/kg total dose) given 3 weeks after mastectomy
Trial: 15483784
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (6 g ethyl ester daily for 16 weeks)
Trial: 15483784
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (SO) supplementation (6 g ethyl ester daily for 16 weeks)
Trial: 7888537
Drug: Didanosine (buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine (buffered powder for oral solution, total daily doses of 6.6‐10 mg/kg)
Trial: 3184196
Drug: CVPP (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone) alone for 6 monthly cycles
Trial: 3184196
Drug: CVPP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVPP plus RT (radiation therapy, 3,000 rad)
Trial: 4880663
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of tetracycline, divided into 4 doses, daily for 5 days
Trial: 4880663
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of tetracycline in a single dose daily for 5 days
Trial: 4880663
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1.0 g of tetracycline
Trial: 4880663
Drug: Multivitamin preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin preparations
Trial: 31200019
Drug: Conventional sample
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sample preparation methods
Trial: 21972615
Drug: Moxibustion at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion at Guanyuan (CV 4) and Shenque (CV 8) in addition to standard treatment
Trial: 21972615
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment including Mifepristone, Rivanol, Misoprostol, uterine curettage, and Oxytocin
Trial: 16738738
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (10 mg/day of zinc sulfate for four months)
Trial: 15327560
Drug: TriAc (0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriAc (0.1% in hydrophilic ointment) applied twice daily for 8 weeks
Trial: 16428147
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 8 weeks
Trial: 8275621
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg candoxatril
Trial: 8275621
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg candoxatril
Trial: 8275621
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg candoxatril
Trial: 28681988
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg/d
Trial: 21225314
Drug: Gemcitabine/cisplatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine/cisplatin plus 7.5 mg/m² rh-endostatin
Trial: 16248237
Drug: Shensong yangxin
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shensong yangxin capsule (SYC)
Trial: 16248237
Drug: Xinlvning tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinlvning tablet (Control)
Trial: 10395121
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of clodronate (400, 800, and 1600 mg) to healthy volunteers
Trial: 10395121
Drug: Clodronate (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (800 and 1600 mg) twice daily for one week to cancer patients
Trial: 10395121
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy with clodronate (400 mg thrice daily) in hospitalized cancer patients
Trial: 8718917
Drug: Pressure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure treatment applied for 10 sec prior to injection
Trial: 8718917
Drug: Standard injection
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard injection with no pressure applied
Trial: 6093487
Drug: 1,25(OH)2D3/l alpha‐OHD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3/l alpha‐OHD3 (0.25 micrograms/day)
Trial: 24508899
Drug: 3-day faropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day faropenem treatment
Trial: 24508899
Drug: 7-day faropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day faropenem treatment
Trial: 22953994
Drug: Group-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based behavioral exercise program (weekly sessions and homework for 6 months)
Trial: 20699432
Drug: Euglycemia (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (5.5 mmol/l)
Trial: 20699432
Drug: Progressive hypoglycemia
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive hypoglycemia (3.9-2.5 mmol/l)
Trial: 1678650
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg intravenously three times a day until the fourth postoperative day (n = 10)
Trial: 31831028
Drug: Dienogest (DNG)
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest (DNG) treatment
Trial: 31831028
Drug: Standard controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard controlled ovarian hyperstimulation with GnRH agonist
Trial: 25525051
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) inactivated influenza vaccine (IIV)